Navigation Links
Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team
Date:1/25/2011

SOUTH PLAINFIELD, N.J., Jan. 25, 2011 /PRNewswire/ -- Prolong Pharmaceuticals, which in October secured a $30 million funding commitment from a private investment group, today announced the signing of a long term lease on a manufacturing facility in South Plainfield, New Jersey and the formal addition of Dr. Hemant Misra to the Prolong Executive Management team as Vice President, Manufacturing and Facilities Operations.

The manufacturing facility has been used by Prolong since early 2010, and has already produced clinical batches of Prolong's oxygen transfer agent, SANGUINATE™, sufficient to take the company through the Phase I and II trials expected to begin this year. "Through this agreement we are able to take tens of millions of dollars and years of time off our product development cycle," said Prolong President Glenn Kazo. "We are already producing large scale biological product in a cGMP environment, and now is the right time to secure our longer term manufacturing facilities. Our fortune in teaming with Hemant and acquiring this particular facility at this time in our corporate history is quite remarkable."

A 30-year veteran of the pharmaceutical industry, Dr. Misra will head the process of bringing the new facility to full capacity. Prior to joining Prolong, Dr. Misra managed manufacturing operations, drug development and clinical studies for XTL Biopharmaceuticals as Vice President. His work has also included management roles as the Director of Clinical Drug Development and Corporate Development at Genzyme Transgenics, a subsidiary of Genzyme Corporation. Previously, Hemant held senior level positions at Activecyte, Inc., a Boston Consulting Group Company, at Chemsyn Science Labs and at Andrulis Pharmaceuticals.

Dr. Misra joins a team of industry leaders which has been assembled at Prolong. In addition to CEO and Scientific Founder Dr. Abraham Abuchowski, Prolong has named Glenn Kazo as President, brought aboard Richard Prince as Vice President, Quality, and added Andy Burger as Vice President, Information Services.

About Prolong Pharmaceuticals

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company, Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. In October 2010, Prolong secured a $30 million funding commitment from a private investor group. For more information visit: www.prolongpharmaceuticals.com


'/>"/>
SOURCE Prolong Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolong Pharmaceuticals Boosts Executive Team
2. Prolong Pharmaceuticals Secures $30 Million in Funding
3. Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President
4. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
5. Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases
6. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
7. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
8. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
9. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
10. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
11. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... and OR AKIVA, Israel , February ... Ltd., a leader in the field of cartilage ... round on February 5, 2016. The $15 million investment ... a leading Chinese pharmaceutical manufacturer, and was joined by ... Generali Financial Holdings and both the Technion Research & ...
(Date:2/10/2016)... KANSAS CITY, Mo. , Feb. 10, 2016 ... the pharmaceutical industry, recently identified an industry-wide trend ... a tool that allows organizations to efficiently deliver ... surveys, one in 2011 and another in 2015, ... are armed with tablet devices and DSAs, many ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... Guard, to associations of medical professionals throughout the country. The Guard was specifically ... assessments, policies and procedures, employee training, regulatory updates, and compliance coaching. , In ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, ... now offering a variety of comprehensive procedures for facial enhancement. The treatments now ... restoration, lip enhancement and nasal reshaping. , As a result, patients can ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former NFL ... a closer look at cases of TBI being managed by their members. The survey ... aging population, and identifies the challenges associated with their care. , During the week ...
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
Breaking Medicine News(10 mins):